This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peng, X. Articles by Mehta, R. G. Search for Related Content PubMed PubMed Citation Articles by Peng, X. Articles by Mehta, R. G. Related Collections Preclinical Intervention Preclinical Intervention: In Vitro: Drugs, Mechanisms

Prohibitin Is a Novel Target Gene of Vitamin D Involved in Its Antiproliferative Action in Breast Cancer Cells

¹ Illinois Institute of Technology Research Institute, Chicago, Illinois; ² University of Illinois at Chicago, Chicago, Illinois; ³ Boston University School of Medicine, Boston, Massachusetts; and ⁴ H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Requests for reprints: Rajendra G. Mehta, Illinois Institute of Technology Research Institute, 10 West 35th Street, Chicago, IL 60616. Phone: 312-567-4970; Fax: 312-567-4931; E-mail: rmehta{at}iitri.org.

Previously, we showed that N-methyl-N-nitrosourea–transformed MCF12F breast epithelial cells exhibited differential expression of several genes, including up-regulation of prohibitin and elevated sensitivity to a relatively noncalcemic vitamin D analogue, 1-hydroxyvitamin D5 [1(OH)D₅]. In this report, we evaluated the functional significance of prohibitin in relation to the cellular response to vitamin D. The in silico screening for putative transcription factor binding sites identified two vitamin D receptor (VDR)/retinoid X receptor binding sites in the 1-kb promoter region of prohibitin. Prohibitin up-regulation by 1(OH)D₅ treatment at both transcriptional and translational levels was confirmed by real-time reverse transcription-PCR and Western blot analysis in breast cancer cells, identifying prohibitin as a vitamin D target gene. Confocal microscopic analysis showed that prohibitin was localized in the nuclei of MCF-7 cells and a portion of prohibitin was colocalized with VDR, but direct physical interaction between VDR and prohibitin in cell lysates was not detectable. In MCF-7 cells expressing tetracycline-inducible prohibitin (Tet-On model), the overexpression of prohibitin inhibited cell proliferation and enhanced vitamin D–induced antiproliferative activity. Knockdown of prohibitin was accompanied by increased number of cells incorporating bromodeoxyuridine in the whole population and increased cell distribution in the S phase of cell cycle. In addition, prohibitin level had no significant effect on the vitamin D–induced transactivation of CYP24, a VDR target gene. This is the first report to suggest that prohibitin serves as a novel vitamin D target gene, which is involved in the antiproliferative action of vitamin D without affecting CYP24 transactivation in breast cancer cells. (Cancer Res 2006; 66(14): 7361-9)

This article has been cited by other articles:

				D. Fuchs, K. Vafeiadou, W. L Hall, H. Daniel, C. M Williams, J. H Schroot, and U. Wenzel Proteomic biomarkers of peripheral blood mononuclear cells obtained from postmenopausal women undergoing an intervention with soy isoflavones Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1369 - 1375. [Abstract] [Full Text] [PDF]

				X. Peng, P. Jhaveri, E. A. Hussain-Hakimjee, and R. G. Mehta Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1{alpha}-hydroxyvitamin D5 Carcinogenesis, May 1, 2007; 28(5): 1000 - 1007. [Abstract] [Full Text] [PDF]